Clinical trial
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of…
NCT00229723 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00229723 |
|---|---|
| Title | IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma |
| Official title | A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multicentre Comparative Study of Gefitinib 250 mg or 500 mg (IRESSA™) Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreated Unresected Late Stage III/IV… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Squamous Cell |
| Intervention type | Drug, Radiation |
| Interventions | gefitinib (Iressa), cisplatin, radiotherapy, Gefitinib (Iressa) |
| Enrollment | 224 |
| Start date | Nov 1, 2004 |
| Completion | Jun 1, 2008 |
| First posted | Sep 30, 2005 |
| Last update posted | Aug 4, 2009 |
| Countries | Belgium, Czechia, Germany, India, Poland, Serbia, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: